scholarly journals Concurrence of Gastric Cancer and Incidental Pulmonary Embolism May Be a Prognostic Factor for Advanced Gastric Cancer Patients with Incidental Pulmonary Embolism

2021 ◽  
Vol Volume 13 ◽  
pp. 7637-7644
Author(s):  
Meiqing Qiu ◽  
Ying Meng ◽  
Huijun Wang ◽  
Li Sun ◽  
Zhen Liu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Pulmonary Embolism ◽  
Prognostic Factor ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Incidental Pulmonary Embolism ◽  
Gastric Cancer Patients

The vascular endothelial growth factor as a predictive and prognostic factor in patients with advanced gastric cancer treated with docetaxel, cisplatin, and 5-florouracil (DCF) regimen.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15191-e15191
Author(s):  
Sedef H. Aktas ◽  
Hakan Akbulut ◽  
Ozan Yazici ◽  
Nurullah Zengin ◽  
Nalan Akgun ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Prognostic Factor ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Predictive Marker ◽  
Vascular Endothelial ◽  
Gastric Cancer Patients ◽  
Endothelial Growth Factor

e15191 Background: Vascular endothelial growth factor (VEGF) is a key element stimulating the angiogenesis in solid tumors. In the current study, we aimed to assess the role of plasma VEGF levels as a prognostic and predictive marker for advanced gastric cancer patients treated with a modified docetaxel, cisplatinum and 5-florouracil (DCF) regimen. Methods: Thirty consecutive patients treated with a modified DCF regimen were included in the study. The plasma VEGF levels of the patients before treatment and following two cycles of chemotherapy were assayed. Results: The modified DCF regimen was well tolerated and yielded a median overall survival (OS) time of 9,0 months and 2-year OS rate of 20%. Good performance status, lower pre-treatment VEGF levels,and decrease in VEGF levels following chemotherapy were found to be independent prognostic factors for OS. Conclusions: The results of the current study suggest that the corrected plasma levels of VEGF could be used as a prognostic factor for advanced gastric cancer patients and a decrease in VEGF levels following 2 cycles of chemotherapy as a predictive marker for patients receiving DCF chemotherapy regimen.

Prognostic Factor Analysis in Advanced Gastric Cancer Patients Treated with Hydroxyurea, Leucovorin, 5-Fluorouracil, and Cisplatin (HLFP Regimen)

2003 ◽  
Vol 21 (1) ◽  
pp. 14-20 ◽  
Author(s):  
Christophe Louvet ◽  
Fabien Carrat ◽  
Frédéric Mal ◽  
May Mabro ◽  
Karine Beerblock ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Factor Analysis ◽  
Prognostic Factor ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Gastric Cancer Patients

Use of inflammation-based prognostic score to predict survival in patients with advanced gastric cancer receiving biweekly docetaxel and S-1 combination chemotherapy.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14624-e14624
Author(s):  
Chikara Kunisaki ◽  
Masazumi Takahashi ◽  
Hidetaka Ono ◽  
Takashi Oshima ◽  
Shoichi Fujii ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factor ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Prognostic Score ◽  
Univariate Analysis ◽  
Prospective Trial ◽  
Hazard Model ◽  
Gastric Cancer Patients ◽  
The Impact

e14624 Background: The Glasgow Prognostic Score (GPS), an inflammation-based prognostic score composed of C-reactive protein (CRP) and albumin measurements, has been reported to be a prognostic factor in patients with various cancers. This study was conducted to determine the prognostic value of GPS for patients with advanced cancer. Methods: The GPS was classified according to a previous study. A total of 83 advanced gastric cancer patients receiving bi-weekly docetaxel/S1 treatment (DS) were included. Correlation of clinicopathological factors and the GPS was assessed. To identify the impact of GPS as prognostic factors for disease-specific survival (DSS) and progression-free survival (PFS), univariate and multivariate analyses were performed. Results: Of these 83 patients, unresectable tumors were observed in 78 patients and recurrent tumors were detected in 5 patients. Of these, 13 patients underwent surgery and 12 patients underwent gastrectomy. There were significant correlations between the GPS and the neutrophil to lymphocyte ratio (NLR). Univariate analysis revealed that the GPS, ECOG-PS and gastrectomy after DS treatment significantly affected prognosis. The Cox proportional regression hazard model showed that the GPS, age and gastrectomy independently influenced DSS, and that the GPS and gastrectomy also influenced PFS. The Cox proportional regression hazard model restricted patients without gastrectomy showed that the GPS and age independently influenced DSS, and that the GPS influenced PFS. Conclusions: The GPS may be an useful prognostic factor for advanced gastric cancer patients receiving uniform first-line treatment (DS). The impact of the GPS should be confirmed in a well-designed prospective trial in many patients.

Role of nk activating receptor (NKP30) in immunosuppression of advanced gastric cancer patients

2001 ◽  
Vol 37 ◽  
pp. S229
Author(s):  
J.C. Lee ◽  
S.R. Park ◽  
S.H. Lee ◽  
M.W. Sung ◽  
D.S. Heo ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Gastric Cancer Patients ◽  
Activating Receptor
Sign in / Sign up

Export Citation Format

Share Document